Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.

Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →

Sysco Corp.

SYYConsumer Staples

Generated Aug 19, 2026, 09:43 PM UTC

analytical score -16

SYY (Sysco Corp.) analytical snapshot. Revenue grew +3.2% YoY to $81.37B. Net margin at 2.25% (expanding ▲). Return on equity 99.89%, ROA 6.83%, ROIC 168.74%. Market cap $39.43B at $82.46 per share. Trailing P/E 22.11, P/S 0.48, P/B 17.17. EV/Operating income ≈ 15.58 (EV $48.12B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -16 (data confidence 82%). Descriptive analytics from public filings — not investment advice.

Market cap

$39.43B

478.18M shares

Price

$82.46

NYQ

P/E (ttm)

22.11

Revenue (FY)

$81.37B

YoY +3.2%

Net margin

2.25%

▲ 0.27pp

Free cash flow

$1.60B

1.97% margin

Risk level

Elevated

Free SEC analysis

— computed from SEC filings, free to read

Free previewRegulatory Analyst

Filings & Ownership

Regulatory Analyst

score 15Stable

80% conf

Latest quarterly report (10-Q) filed Apr 29, 2026. 17 recent 8-K material-event filings in the index. Recent insider Form 4s: 0 buy vs 0 sell transactions.

Latest quarterly report (10-Q) filed Apr 29, 2026.
17 recent 8-K material-event filings in the index.
Recent insider Form 4s: 0 buy vs 0 sell transactions.
~10,000+ recent 13F-HR filings reference Sysco Corp.; broad institutional reporting.
Recent filers include LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA.
20 recent 13G passive institutional ownership notices.

Latest 10-K

—

Latest 10-Q

Apr 29, 2026

8-K (recent)

Insider net

—

0B/0S

13F filers

10k+

Activist 13D

Recent 13F institutional filers (SEC EDGAR full-text)

Filer	Form	Filed
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA	13F-HR	Aug 9, 2002
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA	13F-HR	May 8, 2001
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA	13F-HR	May 15, 2003
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA	13F-HR	May 11, 2004
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA	13F-HR	Nov 2, 2001

Recent 8-K material events

Date	Form	Description
Aug 12, 2026	8-K	FORM 8-K
Aug 4, 2026	8-K	8-K
Jul 2, 2026	8-K	FORM 8-K
May 18, 2026	8-K	FORM 8-K
Apr 28, 2026	8-K	8-K
Apr 20, 2026	8-K	8-K
Apr 2, 2026	8-K	8-K
Mar 30, 2026	8-K	FORM 8-K

Sources:SEC EDGAR — Company Filings SEC EDGAR — Full-Text Search

Free previewSEC Filing Analyst

SEC Filing Deep-Analysis

SEC Filing Analyst

score -61Deteriorating

64% conf

4 risk signal(s), 1 positive signal(s), 1 watch item(s) detected from XBRL filing diff analysis. Free cash flow declined despite stable or rising capex, indicating the cash burn is operational rather than investment-driven. This is a structural concern — cost reduction or asset sales may be needed to restore FCF.

Free cash flow deteriorating: FCF declined +25.6% YoY (from $2.16B to $1.60B). With OCF at $2.51B and capex at $906.0M, cash generation capacity is weakening — monitor for dividend/buyback sustainability.
NEW: Going concern doubt in latest filing: The term "going concern" "substantial doubt" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 3 filing(s).
NEW: Substantial doubt about ability to continue in latest filing: The term "substantial doubt" "ability to continue" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 3 filing(s).
Restatement of financial statements: The term "restatement of" "previously issued" appears in 2 recent filing(s) (vs 1 in the prior period). This risk language is ongoing.
Operating cash flow exceeds net income: OCF is 1.37x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
NEW: Impairment charge: Impairment charge appears in recent filings but not in the prior 24-month period. Monitor for materiality.
Endogenous analysis: Free cash flow declined despite stable or rising capex, indicating the cash burn is operational rather than investment-driven. This is a structural concern — cost reduction or asset sales may be needed to restore FCF.
Endogenous analysis: The combination of explicit "going concern" language in the filing with deteriorating cash flow or rising leverage is a severe warning signal — the company's own auditors have flagged doubt about the ability to continue as a going concern.
3 new XBRL disclosure(s) in latest filing — expanding reporting scope.
20 disclosure(s) dropped from prior year — reduced reporting granularity.
3 new risk-language term(s) detected in filing text: Going concern doubt, Substantial doubt about ability to continue, Impairment charge.
Ongoing high-severity risk language: Restatement of financial statements.

Revenue

$81.37B

+3.2% YoY

Gross profit

$14.97B

+2.5% YoY

Operating income

$3.09B

-3.6% YoY

Net income

$1.83B

-6.5% YoY

Operating cash flow

$2.51B

-16.0% YoY

Capex

$906.0M

+8.9% YoY

Total assets

$26.77B

+7.5% YoY

Long-term debt

$10.59B

-17.9% YoY

Filing quality score

76/100

3 new disclosures

SEC XBRL metric changes (latest annual vs prior)

Metric	Prior year	Latest year	Change	% Change
Revenue	$78.84B	$81.37B	$2.53B	+3.2%
Gross profit	$14.61B	$14.97B	$361.0M	+2.5%
Operating income	$3.20B	$3.09B	$-114.0M	-3.6%
Net income	$1.96B	$1.83B	$-127.0M	-6.5%
Operating cash flow	$2.99B	$2.51B	$-479.0M	-16.0%
Capex	$832.0M	$906.0M	$74.0M	+8.9%
Total assets	$24.92B	$26.77B	$1.86B	+7.5%
Long-term debt	$12.90B	$10.59B	$-2.31B	-17.9%
Cash & equivalents	$696.0M	$1.07B	$375.0M	+53.9%
Stockholders equity	$1.86B	$1.83B	$-30.0M	-1.6%
Inventory	$1.77B	$2.07B	$302.2M	+17.1%
Interest expense	$113.4M	$128.5M	$15.1M	+13.3%

XBRL disclosure changes (new vs dropped concepts)

Type	Concepts
Added	AssetsFairValueDisclosure, CashAndCashEquivalentsFairValueDisclosure, FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
Removed	AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue, AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue, CapitalizedComputerSoftwareGross, CashSurrenderValueOfLifeInsurance, CurrentIncomeTaxExpenseBenefit, DebtAndCapitalLeaseObligations, DeferredIncomeTaxExpenseBenefit, DeferredIncomeTaxLiabilities, DeferredTaxAssetInterestCarryforward, DeferredTaxAssetsGross

Risk language in filing text (EDGAR full-text search)

Term	Severity	Recent	Prior	Status
Going concern doubt	high	3	0	NEW
Substantial doubt about ability to continue	high	3	0	NEW
Restatement of financial statements	high	2	1	Ongoing
Impairment charge	medium	5	0	NEW
Restructuring	medium	5	9	Ongoing
Off-balance sheet arrangements	medium	5	2	Ongoing
Related party transactions	low	5	1	Ongoing

Filing signal breakdown

Red flags: 4

Positive: 1

Watch: 1

Red flags

Positive

Watch

Sources:SEC EDGAR — Company Facts (XBRL)SEC EDGAR — Financial Reports

Free previewFundamentals Analyst

Fundamentals

Fundamentals Analyst

score 0Stable

80% conf

Revenue grew +3.2% YoY to $81.37B. Net margin at 2.25% (expanding ▲). Return on equity 99.89%, ROA 6.83%, ROIC 168.74%.

Revenue grew +3.2% YoY to $81.37B.
Net margin at 2.25% (expanding ▲).
Return on equity 99.89%, ROA 6.83%, ROIC 168.74%.
Gross margin 18.40%, operating margin 3.80%.
Free cash flow margin 1.97% ($1.60B).
Net income down ▼ +6.5% YoY.
Debt/equity 4.61, current ratio 1.33, net debt $8.69B.
Asset turnover 2.91 — capital efficiency.

Revenue (FY)

$81.37B

YoY +3.2%

Net margin

2.25%

▲ 0.27pp

ROE

99.89%

ROA 6.83%

ROIC

168.74%

EPS (diluted)

$3.73

FY2025

Free cash flow

$1.60B

1.97% margin

Debt / equity

4.61

Cash $1.90B

Current ratio

1.33

Equity $2.30B

Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)

FY	Revenue	Rev YoY	Gross%	Op%	Net%	FCF	ROE%
2024	$78.84B	+3.3%	18.53	4.06	2.48	$2.16B	105.11
2025	$81.37B	+3.2%	18.40	3.80	2.25	$1.60B	99.89

Quarterly revenue trend (last 6 quarters, SEC 10-Q)

Quarter end	Revenue	YoY	QoQ	Net margin
Sep 28, 2024	$20.48B	—	—	2.39%
Dec 28, 2024	$20.15B	—	-1.6%	2.01%
Mar 29, 2025	$19.60B	—	-2.7%	2.05%
Sep 27, 2025	$21.15B	—	+7.9%	2.25%
Dec 27, 2025	$20.76B	—	-1.8%	1.87%
Mar 28, 2026	$20.52B	—	-1.2%	1.66%

Sources:SEC EDGAR — Company Facts (XBRL)

+8 more years of history, charts & full breakdown Pro

Pro analysis — preview

— score, signals & key metrics shown; full reasoning locked

Valuation

Valuation Analyst

score -60Deteriorating

95% conf

Market cap $39.43B at $82.46 per share. Trailing P/E 22.11, P/S 0.48, P/B 17.17. EV/Operating income ≈ 15.58 (EV $48.12B).

Market cap $39.43B at $82.46 per share.

Market cap

$39.43B

478.18M shares

P/E (ttm)

22.11

P/S

0.48

P/B

17.17

$48.12B

Intrinsic (DCF)

$54.61

-33.8% vs price

ProFull breakdown & reasoning locked

Price & Technicals

Technical Analyst

score 45Improving

85% conf

Price $82.46 — uptrend (above 200-DMA); 1-month momentum positive. RSI(14) 37.89.

Price $82.46 — uptrend (above 200-DMA); 1-month momentum positive.

Price

$82.46

NYQ

RSI(14)

37.89

50-DMA

$82.13

200-DMA

$78.85

Volatility (ann.)

27.69%

52w range

$68.19–$91.85

-10.2% from high

ProFull breakdown & reasoning locked

Macro & Rates

Macro Analyst

score 30Improving

80% conf

Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.

Market regime: Risk-on · Supportive.

GDP growth

1.50%

CPI (YoY)

+3.3%

Fed funds

3.63%

10Y yield

4.71%

10Y−2Y

0.46pp

Unemployment

4.10%

ProFull breakdown & reasoning locked

Risk Scorecard

Risk Analyst

score -18Deteriorating

83% conf

Composite risk Elevated. Leverage debt/equity 4.61 (high). Liquidity current ratio 1.33 (adequate).

Composite risk: Elevated.

Risk level

Elevated

Debt / equity

4.61

Current ratio

1.33

Margin stdev

1.08pp

Cash / assets

6.79%

Liab / assets

—

ProFull breakdown & reasoning locked

See the full picture behind every stock

Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.

Subscribe to Pro Create free account

3 sections free · 4 Pro previews · composite -16

Macro exposure

Defensive · Low sensitivity

Neutral

Macro regime: Risk-on · Supportive. Sysco Corp. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.

Macro regime

Risk-on · Supportive

Yield curve

Normal

VIX

15.84

Fed funds

3.63%

CPI YoY

+3.3%

Analytical read

deterministic preview

Price $82.46 — uptrend (above 200-DMA); 1-month momentum positive..

Risk

Elevated

Macro regime

Risk-on · Supportive

Macro exposure

Neutral

Descriptive analytics from public filings and macro data — not investment advice.

Open analytical workspace

Peer comparison

Defensive group

How SYY stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.

Company	Score	Macro
DexCom Inc. DXCM	21	Neutral
Bristol-Myers Squibb BMY	19	Neutral
Eli Lilly & Co. LLY	17	Neutral
Gilead Sciences GILD	10	Neutral
HCA Healthcare HCA	9	Neutral
Johnson & Johnson JNJ	9	Neutral
Intuitive Surgical Inc. ISRG	9	Neutral
Biogen Inc. BIIB	7	Neutral
Abbott Laboratories ABT	7	Neutral
Coca-Cola Co. KO	6	Neutral
Thermo Fisher Scientific TMO	3	Neutral
Regeneron Pharmaceuticals REGN	3	Neutral
Merck & Co. MRK	3	Neutral
Colgate-Palmolive CL	2	Neutral
Danaher Corp. DHR	1	Neutral
Zoetis Inc. ZTS	0	Neutral
Vertex Pharmaceuticals VRTX	0	Neutral
Illumina Inc. ILMN	-2	Neutral
AbbVie Inc. ABBV	-5	Neutral
Costco Wholesale COST	-6	Neutral
Procter & Gamble PG	-7	Neutral
CVS Health Corp. CVS	-8	Neutral
Amgen Inc. AMGN	-10	Neutral
Cigna Group CI	-11	Neutral
Mondelez International MDLZ	-12	Neutral
Kroger Co. KR	-13	Neutral
Pfizer Inc. PFE	-13	Neutral
Walmart Inc. WMT	-14	Neutral
PepsiCo Inc. PEP	-16	Neutral
Sysco Corp. SYY● you	-16	Neutral
Kimberly-Clark Corp. KMB	-18	Neutral
Hershey Co. HSY	-21	Neutral
Moderna Inc. MRNA	-21	Neutral
UnitedHealth Group UNH	-25	Neutral